SallyJYorkMD

Oncology • Nashville, TN

Hematologic Oncology, Thoracic Cancer

Associate Professor, Medicine, Vanderbilt University School of Medicine

Join to view full profile

Dr. York is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. York's full profile

Already have an account?

Office
3601 Pierce Ave
Nashville, TN 37232
Phone+1 615-936-2000

Fax+1 615-936-0605

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2001
Duke University HospitalResidency, Internal Medicine, 1996 - 1999
Washington University in St. Louis School of MedicineClass of 1996

Certifications & Licensure

TN State Medical License 2012 - 2026
AL State Medical License 2020 - 2020
NC State Medical License 1997 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, Leora Horn, D Ross Camidge
Clinical Cancer Research. 2025-02-17
Afatinib and Necitumumab in-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.
Nathaniel J Myall, Jennifer G Whisenant, Joel W Neal, Wade T Iams, Karen L Reckamp
JTO Clinical and Research Reports. 2025-02-01
National Survey of Lung Cancer Screening Eligibility in United States Veterans.
Jennifer A Lewis, Allison Stranick, Jacquelyn Pennings, Lauren R Samuels, Susan Byerly
American Journal of Preventive Medicine. 2025-01-27

Press Mentions

VICC Helps Expand Cancer Patient’s Treatment OptionsJanuary 14th, 2016